Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial

Autor: Cramer, Paula *, Fürstenau, Moritz, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fink, Anna-Maria, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Tausch, Eugen, Schneider, Christof, Schetelig, Johannes, Dreger, Peter, Böttcher, Sebastian, Kreuzer, Karl-Anton, Schilhabel, Anke, Ritgen, Matthias, Brüggemann, Monika, Kneba, Michael, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael
Zdroj: In The Lancet Haematology October 2022 9(10):e745-e755
Databáze: ScienceDirect